Suscribirse

Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19 - 03/11/22

Doi : 10.1016/j.jaci.2022.09.005 
Hassan Abolhassani, MD, PhD a, c, Samaneh Delavari, MSc c, Nils Landegren, MD, PhD b, f, Sima Shokri, MD g, Paul Bastard, MD, PhD h, i, j, Likun Du, PhD a, Fanglei Zuo, PhD a, Reza Hajebi, MD d, Farhad Abolnezhadian, MD k, Sara Iranparast, MD l, Mohammadreza Modaresi, MD e, Ahmad Vosughimotlagh, MD m, Fereshte Salami, MSc c, Maribel Aranda-Guillén, PhD b, Aurélie Cobat, MD, PhD i, j, Harold Marcotte, PhD a, Shen-Ying Zhang, MD, PhD h, i, j, Qian Zhang, MD h, i, Nima Rezaei, MD, PhD c, Jean-Laurent Casanova, MD, PhD h, i, j, n, Olle Kämpe, MD, PhD b, o, Lennart Hammarström, MD, PhD a, , Qiang Pan-Hammarström, MD, PhD a,
a Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Huddinge, Sweden 
b Centre for Molecular Medicine, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden 
c Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran 
d Department of General Surgery, School of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran 
e Division of Pediatrics Pulmonary Disease, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran 
f Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden 
g Department of Pediatrics, School of Medicine, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran 
h St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 
i Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France 
j University of Paris, Imagine Institute, Paris, France 
k Department of Pediatrics, Abuzar Children’s Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 
l Department of Immunology, Faculty of Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 
m Department of Pediatrics, North Khorasan University of Medical Sciences, Bojnurd, Iran 
n Howard Hughes Medical Institute, New York, NY 
o Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden 

Corresponding author: Qiang Pan-Hammarström, MD, PhD, or Lennart Hammarström, MD, PhD, NEO/PHA Group, Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83 Huddinge, Sweden.NEO/PHA GroupDepartment of Biosciences and NutritionKarolinska InstitutetHuddingeSE-141 83Sweden

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Most severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected individuals are asymptomatic or only exhibit mild disease. In about 10% of cases, the infection leads to hypoxemic pneumonia, although it is much more rare in children.

Objective

We evaluated 31 young patients aged 0.5 to 19 years who had preexisting inborn errors of immunity (IEI) but lacked a molecular diagnosis and were later diagnosed with coronavirus disease 2019 (COVID-19) complications.

Methods

Genetic evaluation by whole-exome sequencing was performed in all patients. SARS-CoV-2–specific antibodies, autoantibodies against type I IFN (IFN-I), and inflammatory factors in plasma were measured. We also reviewed COVID-19 disease severity/outcome in reported IEI patients.

Results

A potential genetic cause of the IEI was identified in 28 patients (90.3%), including mutations that may affect IFN signaling, T- and B-cell function, the inflammasome, and the complement system. From tested patients 65.5% had detectable virus-specific antibodies, and 6.8% had autoantibodies neutralizing IFN-I. Five patients (16.1%) fulfilled the diagnostic criteria of multisystem inflammatory syndrome in children. Eleven patients (35.4%) died of COVID-19 complications. All together, at least 381 IEI children with COVID-19 have been reported in the literature to date. Although many patients with asymptomatic or mild disease may not have been reported, severe presentation of COVID-19 was observed in 23.6% of the published cases, and the mortality rate was 8.7%.

Conclusions

Young patients with preexisting IEI may have higher mortality than children without IEI when infected with SARS-CoV-2. Elucidating the genetic basis of IEI patients with severe/critical COVID-19 may help to develop better strategies for prevention and treatment of severe COVID-19 disease and complications in pediatric patients.

El texto completo de este artículo está disponible en PDF.

Key words : Inborn errors of immunity, primary immunodeficiency, SARS-CoV-2, COVID-19, multisystem inflammatory syndrome in children (MIS-C), genetic diagnosis, immune response

Abbreviations used : ACMG, CID, COVID-19, HRCT, ICU, IEI, IFN-I, IUIS, KD, MIS-C, NF-κB, PAD, RBD, SARS-CoV-2, TLR, WES


Esquema


 This project received funding from the European Union’s Horizon 2020 research and innovation program (ATAC, 101003650), the Swedish Research Council, the Swedish Cancer Society, Jeffrey Modell Foundation and the Knut and Alice Wallenberg Foundation (KAW). The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R01AI163029), the National Center for Advancing Translational Sciences, NIH Clinical and Translational Science Award program (UL1TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Fisher Center for Alzheimer's Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), ANR grants (ANR-14-CE14-0008-01, ANR-18-CE15-0020-02, ANR-20-CE93-003, ANR-20-CO11-000,1 and ANR-21-COVR-0039), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCovid project (ANR-20-COVI-0003), ANRS Nord-Sud (ANRS-COV05), the European Union’s Horizon 2020 research and innovation program under grant 824110 (EASI-Genomics), the Square Foundation, Grandir-Fonds de solidarité pour l’enfance, the SCOR Corporate Foundation for Science, Fondation du Souffle, Institut National de la Santé et de la Recherche Médicale (Inserm), REACTing-INSERM, and the University of Paris. P.B. was supported by the French Foundation for Medical Research (FRM, EA20170638020). P.B. was supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller).
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2022  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 150 - N° 5

P. 1059-1073 - novembre 2022 Regresar al número
Artículo precedente Artículo precedente
  • The time to PREPARE is over; the time to improve diversity in asthma studies is now
  • L. Keoki Williams
| Artículo siguiente Artículo siguiente
  • Deep immunophenotyping reveals biomarkers of multisystemic inflammatory syndrome in children in a Latin American cohort
  • Emma Rey-Jurado, Yazmin Espinosa, Camila Astudillo, Lina Jimena Cortés, Juan Hormazabal, Loreani P. Noguera, Fernanda Cofré, Cecilia Piñera, Ricardo González, Alexander Bataszew, Paula Muñoz Venturelli, Dona Benadof, Patricia Álvarez, Valeria Acevedo, Pablo Vial, Cecilia Vial, M. Cecilia Poli

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.